安国市那个算命先生算事业比较准(吉林找算命好的大师) (今日更新中)

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

WASHINGTON, April 4 (Xinhua) -- New research from the University of Pennsylvania School of Medicine has revealed an increased incidence of major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death, in patients with severe psoriasis. The study results were reported Monday at the annual American College of Cardiology meeting in New Orleans.Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular disease. However, the degree to which psoriasis is associated with MACE has not been defined.In a cohort study analyzing data from a general practice research database, Lead author Nehal Mehta, director of Inflammatory Risk in Penn's Preventive Cardiology program, and colleagues reviewed the case histories of over 3,600 patients with severe psoriasis and 14,300 controls. They found that patients with severe psoriasis have a 53 percent increased incidence of MACE compared to the general population. They also found that having a diagnosed case of severe psoriasis confers an additional ten-year risk of six percent on MACE.Previous work from Mehta and colleagues found that the risk of death from cardiovascular disease increased by 57 percent in patients with severe psoriasis. In addition, the relative risk of death from cardiovascular disease was even higher in younger patients, who were as young as age 40.The researchers conclude that this new estimate of increased ten-year MACE may warrant more aggressive strategies for treatment of cardiovascular risk factors in patients with psoriasis.

JERUSALEM, May 8 (Xinhua) -- Israeli researcher Jacob (Koby) Scheuer, from the Tel Aviv University (TAU) School of Electrical Engineering, has developed a nano-scale gyroscope, the Ha'aretz daily reported Sunday.Scheuer developed a new optic-fiber nano-sensor four years ago, along with an optic gyroscope that works in conjunction with the sensor. As he developed the devices, it occurred to him that his discovery could be harnessed to surgical needs, virtual reality, or communications, said the report."What we developed here is an optic gyroscope," Scheuer told Xinhua in a recent interview on Sunday, "like the others, but the breakthrough is that we found a way to measure rotation in a very, very small device using the optic sensor."Optic gyroscopes emit light when they rotate, and change its wavelength when there is any change in the speed of rotation, making it possible to measure velocity and position by the differences in light.Scheuer's gyroscope, however, is so small in comparison to the others commonly used in planes, trains and vehicles, that it can be used in cell phones or watches and does not need satellite connection like the ubiquitous Global Positioning System.The applications of this gyroscope and optic sensor are almost endless, as Scheuer puts it."It can be a pill that you swallow and can move through your body to take pictures or release drugs in a localized area," the researcher explained, "or it can be used by a doctor to operate on a patient who is thousands of kilometers away.""Our gyroscope has complete independent navigation capability, which the others don't have," he stressed.Though the new optic gyroscope works in theory, it still hasn't been tried in out in reality. "It will take some time until we can empirically demonstrate our work, I would say about three to five years," Scheuer added.Alongside the gyroscope, Scheuer continues to work on the optic sensor, whose applications can also be found in security, such as an information security system developed by Scheuer to safeguard online information that acts as a key bearer."When both parties have 'the key' it's virtually impossible to hack the information sent," Scheuer noted, terming the development as a "total paradigm change."

LOS ANGELES, April 14 (Xinhua) -- Customer complaints of an "uncharacteristic odor" prompted Johnson & Johnson to recall about 57,000 bottles of the prescription anti-seizure drug, Johnson & Johnson announced on Thursday.The recall affects two lots of the Topamax 100 mg tablets made by the company's Ortho-McNeil Neurologics division, Johnson & Johnson said.The drug was shipped and distributed between Oct. 19, 2010 and Dec. 28, 2010 in the United States and Puerto Rico.There were four consumer complaints about an odor believed to be caused by trace amounts of the chemical TBA (2,4,6 tribromoanisole), which is applied to wooden pallets used to transport and store packaging materials, Johnson & Johnson said.The recall is not expected to lead to a product shortage at the market, Ortho-McNeil Neurologics said.Similar complaints of a moldy, musty odor have led to the recalls of millions of bottles of Tylenol, Motrin and Benadryl products earlier.Last month, the U.S. government said it was taking over three Tylenol plants operated by McNeil, and the Food and Drug Administration launched a criminal investigation into safety issues at the factories, CNN reported.

WASHINGTON, May 4 (Xinhua) -- The U.S. National Aeronautics and Space Administration (NASA) announced Wednesday that its Gravity Probe B (GP-B) mission has confirmed two key predictions derived from Albert Einstein's general theory of relativity, which the spacecraft was designed to test.The experiment, launched in 2004, used four ultra-precise gyroscopes to measure the hypothesized geodetic effect, the warping of space and time around a gravitational body, and frame- dragging, the amount a spinning object pulls space and time with it as it rotates.GP-B determined both effects with unprecedented precision by pointing at a single star, IM Pegasi, while in a polar orbit around Earth. If gravity did not affect space and time, GP-B's gyroscopes would point in the same direction forever while in orbit. But in confirmation of Einstein's theories, the gyroscopes experienced measurable, minute changes in the direction of their spin, while Earth's gravity pulled at them.The findings are available online in the journal Physical Review Letters."Imagine the Earth as if it were immersed in honey. As the planet rotates, the honey around it would swirl, and it's the same with space and time," said Francis Everitt, GP-B principal investigator at Stanford University. "GP-B confirmed two of the most profound predictions of Einstein's universe, having far- reaching implications across astrophysics research."GP-B is one of the longest running projects in NASA history, with agency involvement starting in the fall of 1963 with initial funding to develop a relativity gyroscope experiment. Subsequent decades of development led to groundbreaking technologies to control environmental disturbances on spacecraft, such as aerodynamic drag, magnetic fields and thermal variations. The mission's star tracker and gyroscopes were the most precise ever designed and produced.GP-B completed its data collection operations and was decommissioned in December 2010."The mission results will have a long-term impact on the work of theoretical physicists," said Bill Danchi, senior astrophysicist and program scientist at NASA Headquarters in Washington. "Every future challenge to Einstein's theories of general relativity will have to seek more precise measurements than the remarkable work GP-B accomplished."

来源：资阳报